These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22475866)

  • 1. Novel pyrrolopyrimidine analogues as potent dipeptidyl peptidase IV inhibitors based on pharmacokinetic property-driven optimization.
    Xie H; Zeng L; Zeng S; Lu X; Zhang G; Zhao X; Cheng N; Tu Z; Li Z; Xu H; Yang L; Zhang X; Huang M; Zhao J; Hu W
    Eur J Med Chem; 2012 Jun; 52():205-12. PubMed ID: 22475866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
    Deng J; Peng L; Zhang G; Lan X; Li C; Chen F; Zhou Y; Lin Z; Chen L; Dai R; Xu H; Yang L; Zhang X; Hu W
    Eur J Med Chem; 2011 Jan; 46(1):71-6. PubMed ID: 21106276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.
    Ji X; Su M; Wang J; Deng G; Deng S; Li Z; Tang C; Li J; Li J; Zhao L; Jiang H; Liu H
    Eur J Med Chem; 2014 Mar; 75():111-22. PubMed ID: 24531224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of an Orally Active and Long-Acting DPP-IV Inhibitor through Property-Based Optimization with an in Silico Biotransformation Prediction Tool.
    Zeng S; Dou W; Li M; Zhou Y; Guo J; Zhao N; Huang H; Zhou Q; Hu W; Ma Y; Zhao X; Xie H
    ChemMedChem; 2020 Aug; 15(16):1608-1617. PubMed ID: 32558296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel DPP-4 inhibitors against diabetes.
    Liu Y; Hu Y
    Future Med Chem; 2014 May; 6(7):793-808. PubMed ID: 24941873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of potent dipeptidyl peptidase IV inhibitors through pharmacophore hybridization and hit-to-lead optimization.
    Zeng S; Xie H; Zeng LL; Lu X; Zhao X; Zhang GC; Tu ZC; Xu HJ; Yang L; Zhang XQ; Hu W
    Bioorg Med Chem; 2013 Apr; 21(7):1749-55. PubMed ID: 23434133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
    Maezaki H; Banno Y; Miyamoto Y; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Sasaki M; Tsubotani S; Tani A; Funami M; Yamamoto Y; Tawada M; Aertgeerts K; Yano J; Oi S
    Bioorg Med Chem; 2011 Aug; 19(15):4482-98. PubMed ID: 21741847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
    Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
    Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.
    Singh S; Roy S; Sethi S; Benjamin B; Sundaram S; Khanna V; Kandalkar SR; Pal C; Kant R; Patra AK; Rayasam G; Mittra S; Saini KS; Paliwal J; Chugh A; Ahmed S; Sattigeri J; Cliff I; Ray A; Bansal VS; Bhatnagar PK; Davis JA
    Eur J Pharmacol; 2011 Feb; 652(1-3):157-63. PubMed ID: 20540938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel xanthine compounds targeting DPP-IV and GPR119 as anti-diabetic agents.
    Li G; Huan Y; Yuan B; Wang J; Jiang Q; Lin Z; Shen Z; Huang H
    Eur J Med Chem; 2016 Nov; 124():103-116. PubMed ID: 27560285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.
    Ammirati MJ; Andrews KM; Boyer DD; Brodeur AM; Danley DE; Doran SD; Hulin B; Liu S; McPherson RK; Orena SJ; Parker JC; Polivkova J; Qiu X; Soglia CB; Treadway JL; VanVolkenburg MA; Wilder DC; Piotrowski DW
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1991-5. PubMed ID: 19275964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and pharmacological characterization of N-[2-({2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor.
    Kato N; Oka M; Murase T; Yoshida M; Sakairi M; Yamashita S; Yasuda Y; Yoshikawa A; Hayashi Y; Makino M; Takeda M; Mirensha Y; Kakigami T
    Bioorg Med Chem; 2011 Dec; 19(23):7221-7. PubMed ID: 22019046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes.
    Wang J; Feng Y; Ji X; Deng G; Leng Y; Liu H
    Bioorg Med Chem; 2013 Dec; 21(23):7418-29. PubMed ID: 24153396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Yoshida T; Akahoshi F; Sakashita H; Kitajima H; Nakamura M; Sonda S; Takeuchi M; Tanaka Y; Ueda N; Sekiguchi S; Ishige T; Shima K; Nabeno M; Abe Y; Anabuki J; Soejima A; Yoshida K; Takashina Y; Ishii S; Kiuchi S; Fukuda S; Tsutsumiuchi R; Kosaka K; Murozono T; Nakamaru Y; Utsumi H; Masutomi N; Kishida H; Miyaguchi I; Hayashi Y
    Bioorg Med Chem; 2012 Oct; 20(19):5705-19. PubMed ID: 22959556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid generation of a novel DPP-4 inhibitor with long-acting properties: SAR study and PK/PD evaluation.
    Xie H; Zeng S; He Y; Zhang G; Yu P; Zhong G; Xu H; Yang L; Wang S; Zhao X; Hu W
    Eur J Med Chem; 2017 Dec; 141():519-529. PubMed ID: 29078995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovering novel α-aminoacyl-containing proline derivatives with potent and selective inhibitory activity against dipeptidyl peptidase IV: design, synthesis, biological evaluation, and molecular modeling.
    Zhang X; Wang J; Su M; Li Z; Li J; Li J; Liu H
    Chem Biol Drug Des; 2012 Dec; 80(6):843-52. PubMed ID: 22726613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors.
    Li Q; Han L; Zhang B; Zhou J; Zhang H
    Org Biomol Chem; 2016 Oct; 14(40):9598-9611. PubMed ID: 27714283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid generation of novel benzoic acid-based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: Scaffold-hopping and prodrug study.
    Li Q; Meng L; Zhou S; Deng X; Wang N; Ji Y; Peng Y; Xing J; Yao G
    Eur J Med Chem; 2019 Oct; 180():509-523. PubMed ID: 31336309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A; Yamamoto K; Kozakai A; Okumura-Kitajima L; Mita Y; Kitano K; Jingu S; Nakaike S
    Eur J Pharmacol; 2011 Mar; 655(1-3):99-107. PubMed ID: 21262219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: use of a carboxylate prodrug to improve bioavailability.
    Ikuma Y; Hochigai H; Kimura H; Nunami N; Kobayashi T; Uchiyama K; Umezome T; Sakurai Y; Sawada N; Tadano J; Sugaru E; Ono M; Hirose Y; Nakahira H
    Bioorg Med Chem; 2015 Feb; 23(4):779-90. PubMed ID: 25596166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.